Initiation therapy with a combination immune modulators and anti-TNF agents in patients with inflammatory bowel disease (IBD) was associated with a decreased likelihood of treatment ineffectiveness for patients with Crohn’s disease (CD) but not ulcerative colitis (UC). This according to a population cohort study in which researchers collected data from persons with CD (n=852) or UC (n=303) from 2001 through 2016 who began treatment with a TNF antagonist. New and/or continuing users of immunomodulators at the time anti-TNF therapy began were considered recipients of combination therapy. They found:
- In patients with CD, combination therapy was associated with a significant decrease in the likelihood of treatment ineffectiveness.
- However, this association was not significant in patients with UC.
- Combination therapy in those the CD was also associated with increased time to first IBD-related hospitalization and switching anti-TNF agents, but not with IBD-related surgery.
Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associated with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study. [Published online ahead of print November 15, 2018]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.11.003.
Must Reads in IBD & Intestinal Disorders
Hospital Colectomy Volume & Complications, Clin Gastroenterol Hepatol; ePub 2019 Mar 7; Egberg, et al
Assessing Quality of Life in Patients with Inflammatory Bowel Disease, Am J Gastroenterol; ePub 2019 Mar 1; Barnes, et al
Adherence to a Gluten-Free Diet in Adults With Celiac Disease, Dig Liver Dis; ePub 2019 Feb 26; Clerx, et al